CHARLOTTESVILLE, Va.,
April 15, 2019 /PRNewswire/
-- Focused Ultrasound Foundation Chairman Neal F. Kassell, MD, was the keynote speaker at
Analyst & Investor Day at the University Club in New York, NY, on April
11. The event was a first-of-its-kind gathering in the field
of focused ultrasound and included key researchers, clinicians,
financial analysts and institutional investors from around the
world. The meeting was hosted by Profound Medical Corp., which
provides a therapeutic platform combining real-time magnetic
resonance imaging and ultrasound technology for the precise,
incision-free ablation of diseased tissue.
Dr. Kassell spoke about the exponential growth of the focused
ultrasound field, the technology's wide range of indications and
mechanisms of action, and the global adoption of focused ultrasound
as a therapeutic platform. Said Dr. Kassell, "This event was a
milestone in the evolution of focused ultrasound, which validates
that the field is transitioning from research to commercialization
as we get closer to this revolutionary technology being widely
available to millions of people worldwide who suffer from a variety
of diseases. I was honored to be part of this group of
forward-thinkers who share our goal of transforming treatment,
improving outcomes and decreasing cost of care – in the shortest
time possible – with this disruptive technology."
A full webcast archive is available at:
https://www.webcaster4.com/Webcast/Page/2039/29965.
(requires free registration)
The meeting agenda is available here:
https://profoundmedical.com/analystmeeting2019/#agenda.
About Focused Ultrasound
Focused ultrasound uses
ultrasound energy guided by real-time imaging to treat tissue deep
in the body without incisions or radiation. Where each individual
beam passes through tissue, there is no effect. But, at the focal
point, the convergence of the multiple beams of focused ultrasound
energy results in many important biological effects, creating the
possibility of treating a variety of medical disorders. Focused
ultrasound is approved in the United
States to treat essential tremor, Parkinson's, uterine
fibroids, pain from bone metastases, and the prostate. The
technology is in various stages of research and development for
more than 100 diseases.
About the Focused Ultrasound Foundation
The Focused
Ultrasound Foundation was created to accelerate the development of
focused ultrasound, an early-stage noninvasive therapeutic
technology with the potential to transform the treatment of many
medical disorders. The Foundation is dedicated to ensuring that
focused ultrasound becomes a mainstream therapy within years, not
decades, and works to fund research, foster collaboration and build
awareness among patients and professionals. Since its establishment
in 2006, it has become the largest nongovernmental source of
funding for focused ultrasound research. www.fusfoundation.org
About Profound Medical Corp.
Profound Medical
(TXS:PRN) markets customizable therapies for incision- and
radiation-free ablation of diseased tissue. Profound is
commercializing TULSA-PRO®, which combines real-time MRI,
robotically-driven transurethral ultrasound and closed-loop thermal
feedback control. Profound has completed enrollment in a
multicenter, prospective clinical trial, which, if successful, is
expected to support its application for approval to market in
the United States. Profound also
markets Sonalleve®, a therapeutic platform that has multiple
regulatory approvals across several indications around the
globe.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/foundation-chairman-shares-focused-ultrasound-growth-at-inaugural-global-investor-conference-300831939.html
SOURCE Focused Ultrasound Foundation